Clinical trial of natural human lymphocyte-derived interleukin 2 in cancer patients: Effects on cytokine production and suppressor cell status (Q67906593)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 January 1991

Language	Label	Description	Also known as
English	Clinical trial of natural human lymphocyte-derived interleukin 2 in cancer patients: Effects on cytokine production and suppressor cell status	scientific article published on 01 January 1991

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1838486%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Clinical trial of natural human lymphocyte-derived interleukin 2 in cancer patients: effects on cytokine production and suppressor cell status (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1838486%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Clinical trial of natural human lymphocyte-derived interleukin 2 in cancer patients: Effects on cytokine production and suppressor cell status (English)

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Gerhard Ehninger

7

object named as

Ehninger G

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1838486%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

author name string

G. Pawelec

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1838486

6 December 2022

H. J. Lenz

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1838486

6 December 2022

E. Schneider

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1838486

6 December 2022

H. J. Bühring

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1838486

6 December 2022

A. Rehbein

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1838486

6 December 2022

P. Baumgärtner

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1838486

6 December 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1838486

6 December 2022

publication date

1 January 1991

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1838486%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

full work available at URL

http://link.springer.com/content/pdf/10.1007/BF02221323.pdf

Portable Document Format

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

http://link.springer.com/article/10.1007/BF02221323/fulltext.html

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

http://link.springer.com/content/pdf/10.1007/BF02221323

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Biotherapy (Dordrecht, Netherlands)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1838486%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1838486%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1838486%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

309-318

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1838486%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

https://scigraph.springernature.com/pub.10.1007/bf02221323

0 references

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

2

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

3

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Relative cloning efficiencies and long-term propagation capacity for T cell clones of highly purified natural interleukin 2 compared to recombinant interleukin 2 in man

6

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Molecular biotherapy

7

2

44

author name string

G Pawelec

publication date

1990

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects

8

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin

11

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Human naive and memory T cells: reinterpretation of helper-inducer and suppressor-inducer subsets

14

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

15

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Tumour necrosis factor-alpha enhances the cytolytic and cytostatic capacity of interleukin-2 activated killer cells

21

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Natural Immunity and Cell Growth Regulation

26

7

13

author name string

E Kedar

publication date

1988

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Recombinant interleukin 2 inhibits pokeweed mitogen-induced proliferation of human adult peripheral blood and cord blood mononuclear cells

27

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Dissection of suppressor cell generation in vitro

30

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Journal of biological response modifiers

31

9

5

author name string

JA Hank

publication date

1990

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Nosocomial sepsis associated with interleukin-2.

32

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Lymphokine-activated suppressor (LAS) cells in patients with gastric carcinoma.

33

1 reference

10.1007/BF02221323

https://api.crossref.org/works/10.1007/BF02221323

6 December 2022

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q67906593&oldid=1785740509"